Exelixis Inc EXEL:NASDAQ

Last Price$21.21Cboe Real-Time Last Sale as of 12:07PM ET 7/01/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.39(1.87%)
Bid (Size)$21.19 (11)
Ask (Size)$21.21 (200)
Day Low / High$20.72 - 21.41
Volume461.1 K

View Biotechnology IndustryPeer Comparison as of 07/01/2022


Exelixis Inc ( NASDAQ )

Price: $21.21
Change: +0.39 (1.87%)
Volume: 461.1 K
12:07PM ET 7/01/2022

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Exact Sciences Corp ( NASDAQ )

Price: $40.27
Change: +0.88 (2.23%)
Volume: 554.6 K
12:08PM ET 7/01/2022

Halozyme Therapeutics Inc ( NASDAQ )

Price: $43.88
Change: -0.12 (0.27%)
Volume: 286.5 K
12:05PM ET 7/01/2022

Neurocrine Biosciences Inc ( NASDAQ )

Price: $98.65
Change: +1.17 (1.20%)
Volume: 144.0 K
12:07PM ET 7/01/2022

Read more news Recent News

Exelixis Shares Rise After BMO Capital Starts Coverage at Outperform
2:11PM ET 6/24/2022 MT Newswires

Exelixis (EXEL) shares were up more than 3% in Friday afternoon trading after BMO Capital initiated the stock coverage at outperform and set the price...

BMO Capital Starts Exelixis at Outperform With $28 Price Target
4:54AM ET 6/24/2022 MT Newswires

Exelixis (EXEL) has an average rating of outperform and price targets ranging from $18 to $35, according to analysts polled by Capital IQ. (MT Newswires...

Exelixis Initiates Phase 3 Trial of Combination Treatment for Metastatic Colorectal Cancer; Shares Gain
10:49AM ET 6/21/2022 MT Newswires

Exelixis (EXEL) said Tuesday it has initiated a phase 3 trial evaluating its XL092 treatment in combination with either atezolizumab or regorafenib in...

Exelixis to Pay BioInvent $25 Million to Discover Cancer Antibodies
6:25AM ET 6/16/2022 MT Newswires

Exelixis (EXEL) said Wednesday that it entered an option and license agreement with Sweden's BioInvent International AB to discover new antibodies for...

View all Commentary and Analysis

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
8:40AM ET 7/01/2022 Zacks

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further...

Exelixis: Becoming A Giant Pharma
11:20AM ET 5/18/2022 Seeking Alpha

Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q1 2022 Results - Earnings Call Transcript
10:15PM ET 5/10/2022 Seeking Alpha

IDNA: A Long Term Prospect, Slowly Overcoming The Bearish Rally
2:21PM ET 4/29/2022 Seeking Alpha

Company Profile

Business DescriptionExelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA. View company web site for more details
Address1851 Harbor Bay Parkway
Alameda, California 94502
Number of Employees484
Recent SEC Filing06/01/20224
President, Chief Executive Officer & DirectorMichael M. Morrissey
Executive Vice President-Business OperationsDana T. Aftab
Chief Financial Officer & Executive Vice PresidentChristopher J. Senner
Chief Scientific Officer & EVP-Scientific StrategyPeter Lamb

Company Highlights

Price Open$20.78
Previous Close$20.82
52 Week Range$15.50 - 23.40
Market Capitalization$6.8 B
Shares Outstanding320.7 M
SectorHealth Technology
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings24.15
Earnings per Share$0.92
Beta vs. S&P 500N/A
Revenue$845.7 M
Net Profit Margin19.60%
Return on Equity13.77%

Analyst Ratings as of 06/22/2022

Consensus RecommendationConsensus Icon
Powered by Factset